Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Citations 2
Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY
P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1005-1006